Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ATR | Q13535 | 20/20 | 0.87 |
| ▸ | ATRIP | Q8WXE1 | 6/20 | 0.87 |
| ▸ | MTOR | P42345 | 5/20 | 0.87 |
| ▸ | TAF1 | P21675 | 3/20 | 0.87 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.87 |
| ▸ | PRKDC | P78527 | 2/20 | 0.87 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.87 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.87 |
| ▸ | ATM | Q13315 | 1/20 | 0.87 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.69 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.69 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9979100 | 1.00 | ATR (0.87) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL9979102 | 1.00 | ATR (0.87) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL31165828 | 1.00 | ATR (0.87) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL31165830 | 1.00 | ATR (0.87) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL9978987 | 0.97 | ATR (0.82) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL31165856 | 0.97 | ATR (0.82) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL9978988 | 0.97 | ATR (0.82) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL23389998 | 0.93 | ATR (1.00) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL2511931 | 0.93 | ATR (1.00) | ATRATRIPMTORTAF1PIK3CA | |
| SCHEMBL2514010 | 0.93 | ATR (1.00) | ATRATRIPMTORTAF1PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 45 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2579877-B1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2014-08-13 | — | — | EP | claimed |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-01-16 | — | — | US | claimed |
| US-8552004-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2013-10-08 | — | — | US | claimed |
| EP-2579877-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | AstraZeneca AB (SE) | 2013-04-17 | — | — | EP | claimed |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2013-01-03 | — | — | US | claimed |
| WO-2011154737-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | claimed |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | claimed |
| US-20250064967-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2025-02-27 | — | — | US | disclosed |
| US-20230330243-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2023-10-19 | — | — | US | disclosed |
| WO-2023126823-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2023-07-06 | — | — | WO | disclosed |
| EP-4171650-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | AstraZeneca UK Limited (GB) | 2023-05-03 | — | — | EP | disclosed |
| WO-2021260579-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | ASTRAZENECA UK LIMITED (GB) | 2021-12-30 | — | — | WO | disclosed |
| US-9421213-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2016-08-23 | — | — | US | disclosed |
| US-8252802-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2012-08-28 | — | — | US | disclosed |
| US-8252802-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2012-08-28 | — | — | US | disclosed |
| US-8252802-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2012-08-28 | — | — | US | disclosed |
| WO-2011154737-A1 | MORPHOLINO PYRIMIDINES AND THEIR USE IN THERAPY | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | WO | disclosed |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
| US-20110306613-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2011-12-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306613-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ATR 2609/4885ATRIP 4540/4885MTOR 732/4885 |
| US-20230330243-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | ATR, ERBB2, ATRIP | ATR 1/4885ATRIP 3/4885MTOR 931/4885 |
| US-20250064967-A1 | COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATR INHIBITOR | ATR, TTI2, TERF2IP | ATR 1/4885ATRIP 6/4885MTOR 3041/4885 |
| US-20130005725-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ATR 2609/4885ATRIP 4540/4885MTOR 732/4885 |
| US-20140018364-A1 | CHEMICAL COMPOUNDS | CYP2C19, ABCG2, CYP2C9 | ATR 2609/4885ATRIP 4540/4885MTOR 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.